WILSON, N.C., Dec. 21, 2011 /PRNewswire/ -- PharmStar
Pharmaceuticals, Inc., (Pink Sheets: PHAR) (the "Company"), today
announced the rollout of its initial marketing plan for the
introduction of its signature product, Aquaprin.
The marketing plan includes a multi-city tour in the United States to present the product to
the medical community. This presentation is designed
specifically for those that have a need to understand the
advantages and benefits of the liquid aspirin derivative, as well
as the line extension products that will be offered using the
Aquaprin technology.
In discussing the tour, CEO Howard
Phykitt said, "It is our belief that Aquaprin can be the
pain reliever that most people will reach for when facing aches and
pains. Doctors and pharmacists will want to fully understand
the product, and we need such a forum to answer questions. Medical
professionals have a need to know about this new tool that we can
provide for their toolbox."
The audience for each presentation will be by invitation only,
and will include professionals that are connected to the medical
industry, as well as financial professionals. The tour will
kick off in Los Angeles, CA on
January 18, 2012, to be followed by
presentations in Raleigh, NC;
Miami, FL; and Dallas, TX over the successive eight weeks.
The remainder of the tour will be announced as dates are
finalized. The presentations will be made by Mr. Phykitt, the
inventor of the technology used to make Aquaprin.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based
drug development, manufacturing and marketing company and the
innovator of the FDA-approved liquid pain reliever, Aquaprin™. In
development since 1993 with over $3
million invested to-date, Aquaprin™ is a liquid derivative
of aspirin, and is now ready for commercialization. Aquaprin™'s
unique, multiple patent-pending formulas are designed to dissolve
nearly instantly in just 1.5 ounces or more of water. This enables
the product to be absorbed into the bloodstream up to 10 times
faster than traditional OTC pain relievers, and with little to no
stomach upset.
PharmStar initially plans to sell Aquaprin™ directly to nursing
homes, outpatient and health care clinics, emergency units of
hospitals nationwide, as well as retail distribution in selected
local markets and third-party websites to be announced. All package
engineering, product stability; shelf life testing and quality
control research has been completed. PharmStar's headquarters are
located in Wilson, NC.
Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within
the meaning of the federal securities laws, commonly identified by
such terms as "believes," "will," "looking ahead," "anticipates,"
"estimates" and other terms with similar meaning. Although the
Company believes that the assumptions upon which its
forward-looking statements are based are reasonable, it can give no
assurance that these assumptions will prove to be correct.
Important factors that could cause actual results to differ
materially from the Company's projections and expectations are
disclosed in the Company's filings with the Securities and Exchange
Commission. All forward-looking statements in this press release
are expressly qualified by such cautionary statements and by
reference to the underlying assumptions.
www.pharmstarinc.com
SOURCE PharmStar Pharmaceuticals, Inc.